Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist

Oncogene

Volumn 34, Issue 19, 2015, Pages 2493-2504

  Ubertini, V ^a   Norelli, G ^b   D'Arcangelo, D ^a   Gurtner, A ^b   Cesareo, E ^a   Baldari, S ^a   Gentileschi, M P ^a   Piaggio, G ^a   Nistico P ^a   Soddu, S ^a   Facchiano, A ^b   Bossi, G ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; MAFF PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN BINDING; PROTEIN P53; SMALL INTERFERING RNA; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR MAFF;

ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENETICS; HEPG2 CELL LINE; HT 29 CELL LINE; HUMAN; IMMUNOLOGY; INFLAMMATION; MCF 7 CELL LINE; METABOLISM; MORTALITY; MUTATION; NEOPLASM; PROGNOSIS; PROMOTER REGION; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

CELL LINE, TUMOR; DNA-BINDING PROTEINS; HEP G2 CELLS; HT29 CELLS; HUMANS; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MAFF TRANSCRIPTION FACTOR; MCF-7 CELLS; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84938076757     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.191     Document Type: Article

References (45)

1. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE et al. Specific P53 mutations are associated with de novo resistance to DOXorubicin in breast cancer patients. Nofure Med 1996; 2:811-814.
2. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 199:861-872.
3. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. Mutp53 gain of function in two mouse models ofLi-Fraumeni syndrome. Cell 2004; 119:847-860.
4. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. Mutp53 gain offunction: reduction oftumor malignancy ofhuman cancer cell lines through abrogation of mutp53 expression. Oncogene 2006; 25: 304-309.
5. Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldinger N, Oren M, Rotter V. Transactivation of the EGR1 gene contributes to mutp53 gain of function. Concer Res 2004; 64: 8318-8327.
6. Bossi G, Marampon F, Maor-Aloni R, Zani B, Rotter V, Oren M et al. Conditional RNA interference in vivo to study mutp53 oncogenic gain of function on tumor malignancy. Cell Cycle 2008; 7:1870-1879.
7. Smith Jr MF, Eidlen D, Brewer MT, Eisenberg SP, Arend WP, Gutierrez-Hartmann A. Human IL-1 receptor antagonist promoter. Cell type-speciic activity and identification of regulatory regions. J Immunol 1992; 149: 2000-2007.
8. Jenkins JK, Drong RF, Shuck ME, Bienkowski MJ, Slightom JL, Arend WP et al. Intracellular IL-1 receptor antagonist promoter: cell type-speciic and inducible regulatory regions. J Immunol 1997; 158: 748-755.
9. Dunn E, Sims JE, Nicklin MJ, O'Neill LA. Annotating genes with potential roles in the immune system: six new members of the IL-1 family. Trends Immunol 2001; 22:533-536.
10. Schreuder H, Tardif C, Trump-Kallmeyer S, Sofientini A, Sarubbi E, Akeson A et al. A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nofure 1997; 386:194-200.
11. Apte RN, Voronov E. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? Immunol Rev 2008; 222:222-241.
12. Zitvogel L, Kepp O, Galluzzi L, Kroemer G. 'Inflammosome in carcinogenesis and anticancer immune responses'. Nof Immunol 2012; 13:343-351.
13. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nofure 2008; 454: 436-444.
14. Dinarello CA. Why not treat human cancer with Interleukin-1 blockade? Concer Mefosfosis Rev 2010; 29: 317-329.
15. Dinarello CA, Simon A, van der Merr JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nofure Rev 2012; 11:633-652.
16. Gurtner A, Starace G, Norelli G, Piaggio G, Sacchi A, Bossi G. Mutp53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function. J Biol Chem 2010; 285: 14160-14169.
17. Gabay C, Smith Jr MF, Eidlen D, Arend WP. Interleukin-1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invesf 1997; 99: 2930-2940.
18. Kim E, Deppert W. Transcriptional activities of mutp53: when mutations are more than a loss. J Cell Biochem 2004; 93:878-886.
19. Quante T, Otto B, Brazdova M, Kejnovska I, Deppert W, Tolstonog GV. Mutp53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity. Cell Cycle 2012; 11: 3290-3303.
20. Scian MJ, Stagliano KE, Anderson MA, Hassan S, Bowman M, Miles MF et al. Tumor-derived p53 muts induce NF-kappaB2 gene expression. Mol Cell Biol 2005; 25: 10097-10110.
21. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A et al. Gain of function of mutp53: the mutp53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Concer Cell 2006; 10:191-202.
22. Zweidler-Mckay PA, Grimes HL, Flubacher MM, Tsichlis PN. Gi-1 encodes a nuclear zinc inger protein that binds DNA and functions as a transcriptional repressor. Mol Cell Biol 1996; 16:4024-4034.
23. Fischer A, Klattig J, Kneitz B, Diez H, Maier M, Holtmann B et al. Hey basic helix-loop-helix transcription factors are repressors of GATA4 and GATA6 and restrict expression of the GATA target gene ANF in fetal hearts. Mol Cell Biol 2005; 25: 8960-8970.
24. Kimura T, Ivell R, Rust W, Mizumoto Y, Ogita K, Kusui C et al. Molecular cloning ofa human MAFF homologue, which speciically binds to the oxytocin receptor gene in term myometrium. Biochem Biophys Res Commun 1999; 264:86-92.
25. Blank V, Small MAF. proteins in mammalian gene control: mere dimerization partners or dynamic transcriptional regulators? J Mol Biol 2008; 376:913-925.
26. Elaraj DM, Weinreich DM, Varghese S, Puhlmann M, Hewitt SM, Carroll NM et al. The role of Interleukin 1 in growth and metastasis in human cancer xenograft. Clin Concer Res 2006; 12: 1088-1096.
27. Puhlmann M, Weinreich DM, Farma JM, Carroll NM, Turner EM, Alexander Jr HR. Interleukin-1beta induced vascular permeability is dependent on induction of endothelial tissue factor (TF) activity. J Tronsl Med 2005; 3:37.
28. Streicher KL, Willmarth NE, Garcia J, Boerner JL, Dewey TG, Ethier SP. Activation of a nuclear factor kappaB/interleukin-1 positive feedback loop by amphiregulin in human breast cancer cells. Mol Concer Res 2007; 5:847-861.
29. Wu S, Meeker WA, Wiener JR, Berchuck A, Bast Jr RC, Boyer CM. Transfection of ovarian cancer cells with tumor necrosis factor-alpha (TNF-alpha) antisense mRNA abolishes the proliferative response to interleukin-1 (IL-1) but not TNF-alpha. Gynecol Oncol 1994; 53:59-63.
30. Li Y, Wang L, Pappan L, Galliher-Beckley A, Shi J. IL-1|3 promotes stemness and invasiveness of colon cancer cells through Zeb1 activation. Mol Concer 2012; 11:87.
31. Germano G, Allavena P, Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine 2008; 43: 374-379.
32. Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging role of inteleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Tronsl Med 2006; 4: 48.
33. Saijo Y, Tanaka M, Miki M, Usui K, Suzuki T, Maemondo M et al. Proinflammatory cytokine IL-1h promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. JImmunol 2002; 169:469-475.
34. Ulich TR, Guo K, Yin S, del Castillo J, Yi ES, Thompson RC et al. Endotoxin-induced cytokine gene expression in vivo. IV. Expression of interleukin-la/AY and interleukin-1 receptor antagonist mRNA during endotoxemia and during endotoxin-initiated local acute inflammation. Am J Pofhol 1992; 141:61-68.
35. Chirivi RG, Garofalo A, Padura IM, Mantovani A, Giavazzi R. Interleukin 1 receptor antagonist inhibits the augmentation of metastasis induced by interleukin 1 or lipopolysaccharide in a human melanoma/nude mouse system. Concer Res 1993; 53: 5051-5054.
36. Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M, Jarosz D et al. Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS ONE 2010; 5: pii e13091.
37. Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression pro-iles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Concer Res 2001; 61: 3124-3130.
38. Muller PA, Vousden KH. p53 mutations in cancer. Nof Cell Biol 2013; 15:2-8.
39. Freed-Pastor WA, Prives C. Mutp53: one name, many proteins. Genes Dev 2012; 26: 1268-1286.
40. Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, Bolden JE et al. Non-cell-autonomous tumor suppression by p53. Cell 2013; 153: 449-460.
41. Bar J, Feniger-Barish R, Lukashchuk N, Shaham H, Moskovits N, Goldinger N et al. Cancer cells suppress p53 in adjacent ibroblasts. Oncogene 2009; 28: 933-936.
42. Addadi Y, Moskovits N, Granot D, Lozano G, Carmi Y, Apte RN et al. p53 status in stromal ibroblasts modulates tumor growth in an SDF1-dependent manner. Concer Res 2010; 70: 9650-9658.
43. Weisz L, Damalas A, Liontos M, Karakaidos P, Fontemaggi G, Maor-Aloni R et al. Mutp53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Concer Res 2007; 67: 2396-2401.
44. Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S et al. Mutant p53 prolongs NF-kB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Concer Cell 2013; 23: 634-646.
45. D'Arcangelo D, Gaetano C, Capogrossi MC. Acidification prevents endothelial cell apoptosis by Axl activation. Circ Res 2002; 91:e4-e12.